We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Hepregen Corporation Presents Results of Liver Toxicity Study at Annual Meeting of the Society of Toxicology

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Hepregen Corporation Presents Results of Liver Toxicity Study at Annual Meeting of the Society of Toxicology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

At the 50th Anniversary of the Annual Meeting of Society of Toxicology (SOT), Hepregen Corporation has announced the successful use of its HepatoPac platform in an in vitro study demonstrating the species-specific liver toxicity of Fialuridine (FIAU). The results of the study are being presented in a poster session. Hepregen Corporation is a leading provider of bioengineered solutions that increase success in drug development in order to improve patient safety.

Researchers from Hepregen Corporation, in collaboration with Alnylam Pharmaceuticals, investigated the acute and chronic toxicity profiles of FIAU and several analogues in Human and Rat HepatoPac. Using multiple endpoints, FIAU exhibited acute (4 day) and chronic (15 day) dose-dependent toxicity in human HepatoPac.

The toxicity was specific to FIAU alone, whereas other nucleoside analogues did not cause toxicity to the same extent. By contrast, Rat Hepatocytes in the HepatoPac platform were not affected by FIAU in the short term and were only mildly impacted chronically, mimicking the species specific in vivo observations.

FIAU, a nucleoside analog that demonstrated promise as an anti-viral therapy, was pulled from clinical trials in 1993 after severe unexpected liver toxicity was observed in patients. No in vitro or in vivo preclinical models predicted the liver liability that was observed in the clinic.

Hepregen Co-Founder and Director of Research, Salman Khetani, Ph.D., commented on the toxicity study, "Traditional in vitro models are very poor predictors of what will be observed in vivo and in the clinic. This study clearly demonstrates the predictive power of the HepatoPac platform."

Co-Founder, President and CEO, Bernadette (Bonnie) Fendrock added, "This collaboration is an excellent example where we have been able to demonstrate the significance of Hepregen's HepatoPac platform. This work combined with validation work from many other companies supports Hepregen's goal - helping our customers reduce risk and increase confidence in drug development so that they can provide the safest drugs to patients."